Considering that the incidence of liver cancer worldwide is ∼900,000 cases (IARC 2020), predicted to increase >55% by 2040,60 ∼25% of the population (median 10–44%56) has the CYP2D6 intermediate phenotype, and the LOH frequency at 22q is 28%, about 50,000 individuals yearly could potentially benefit from LOH therapies targeting lack of CYP2D6 function by 2040. This evidence concerns the gene CYP2D6 and liver cancer.